Translational Research: Screening

Screening for small molecule or non-viral biologics may involve a variety of approaches at differing scales. Some examples are high throughput screening of millions of small molecules in a cellular assay, testing a few hundred FDA-approved compounds in an ex vivo culture system, or panning through a phage-display library for neutralizing peptides.

Starting Points

Disease
Biology
Unvalidated
Target

Target ID

Putative
Targets
Nominated
Target

Assay Development

Screenable
Assays
Target Assay

Screening

Hits and
Starting Points
Hit

Hit to Lead

Lead Series
Lead
Compound

Lead
Optimization

Potential
Therapeutic
Leads
Pre‑clinical
Candidate

Pre‑clinical
Development

Clinical
Therapeutic
Candidate
Clinical
Candidate

Clinical
Development

Clinical Proof
of Concept
Licensing and
Commercializa-
tion Partners

Market-ready
Therapeutics

Outcomes and Resources

NIH Funding Opportunities

PA-16-374, Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK (R01) has expired. The NIDDK is still interested in supporting this type of translational science and another potential option is to apply to the Parent R01 NOFO (PA-20-185) and consider requesting review assignment to any of CSR’s Drug Synthesis, Discovery, Disposition, and Xenobiotics study sections, or another relevant review panel. Applicants should consult the NIH/CSR study section descriptions before requesting a specific review panel.

Please reach out to one of the Staff Contacts listed below if you have any questions.

Related Resources

Staff Contacts

Division of Kidney, Urologic, and Hematologic Diseases
Dr. Anna Sadusky

Division of Digestive Diseases and Nutrition
Dr. Bonnie Burgess-Beusse

Division of Diabetes, Endocrinology, and Metabolic Diseases
Dr. Yan Li

Last Reviewed October 2024